Tumor immunity meets autoimmunity: Antigen levels and dendritic cell maturation

Current Opinion in Immunology

Volumn 15, Issue 6, 2003, Pages 725-730

  Spiotto, Michael T ^a   Fu, Yang Xin ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR; TUMOR ANTIGEN; TUMOR VACCINE; VIRUS VECTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CANCER THERAPY; CELL DEATH; CELL MATURATION; DENDRITE; EXTRACELLULAR SPACE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MATURATION; NONHUMAN; REVIEW; T LYMPHOCYTE; TISSUE GROWTH; TUMOR IMMUNITY;

EID: 0242575283     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2003.09.018     Document Type: Review

References (48)

1. Schreiber H: Tumor immunology. In Fundamental Immunology, edn 5. Edited by Paul W. Philadelphia: Lippincott-Raven Publishers; 2003: 1557-1593.
2. Starr T.K., Jameson S.C., Hogquist K.A. Positive and negative selection of T cells. Annu. Rev. Immunol. 21:2003;139-176 A comprehensive review of thymic selection.
3. Fu Y.X., Chaplin D.D. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 17:1999;399-433.
4. Goodnow C: Tolerance and loss of tolerance to self tissues. In Immunobiology: The Immune System in Health and Disease, edn 5. Edited by Janeway CATT, Walport M, Shlomchik M. New York: Garland Publishing; 2001: 533-545.
5. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., Zinkernagel R.M. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U S A. 96:1999;2233-2238.
6. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., Zinkernagel R.M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:2001;1058-1064.
7. Kurts C., Miller J.F., Subramaniam R.M., Carbone F.R., Heath W.R. Major histocompatibility complex class I restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188:1998;409-414.
8. Spiotto M.T., Yu P., Rowley D.A., Nishimura M.I., Meredith S.C., Gajewski T.F., Fu Y.X., Schreiber H. Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:2002;737-747 Using a tamoxifen-regulated Cre-loxP system, an inducible cancer cell line is generated to show that only solid tumors expressing higher levels of antigen induce an immune response. This article also suggests that the tumor stroma determines the level of antigen necessary to induce an immune response.
9. + T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. U S A. 96:1999;12703-12707.
10. + T cell tolerance to peripherally expressed antigens. J. Immunol. 163:1999;723-727.
11. Kleindienst P., Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J. Immunol. 170:2003;2817-2823 This article shows that endogenous DCs are necessary for peptide-loaded DCs to induce an immune response, suggesting that effective immune responses require the re-presentation of antigen by a second APC in the DLN.
12. Carbone F.R., Kurts C., Bennett S.R., Miller J.F., Heath W.R. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today. 19:1998;368-373.
13. Juprelle-Soret M., Wattiaux-De Coninck S., Wattiaux R. Subcellular localization of transglutaminase: effect of collagen. Biochem. J. 250:1988;421-427.
14. + T cells. J. Exp. Med. 197:2003;643-656 This article demonstrates that antigen-specific T cells can lyse endothelial cells in islet-organ cultures and adhere to endothelial cell monolayers, suggesting that cross-presentation of antigen by endothelial cells is a major pathway for antigen presentation at the tissue site.
15. Robinson B.W., Scott B.M., Lake R.A., Stumbles P.A., Nelson D.J., Fisher S., Marzo A.L. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis - implications for tumor tolerance. Clin. Cancer Res. 7:2001;S811-S817.
16. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., Speiser D.E., Ohashi P.S. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195:2002;423-435 This article demonstrates that tumor growth can enhance cross-presentation and enhance the activation of high-avidity T cells. Although it is difficult to dissect how tumor growth affects cross-presentation and T cell activation, it is interesting to speculate how these processes may be linked.
17. Horwitz M.S., Ilic A., Fine C., Rodriguez E., Sarvetnick N. Presented antigen from damaged pancreatic β cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J. Clin. Invest. 109:2002;79-87 This study demonstrates that islet destruction is required to release sequestered antigen and induce diabetes, indicating that viral destruction of somatic cells can release antigens and induce immune responses to antigens that are normally ignored.
18. + T cells. J. Immunol. 170:2003;4905-4913 Demonstrating that increased cell death in tumors can enhance cross-presentation, this report shows that low dose chemotherapy may be immunostimulatory.
19. Dyall R., Bowne W.B., Weber L.W., LeMaoult J., Szabo P., Moroi Y., Piskun G., Lewis J.J., Houghton A.N., Nikolic-Zugic J. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1998;1553-1561.
20. Overwijk W.W., Tsung A., Irvine K.R., Parkhurst M.R., Goletz T.J., Tsung K., Carroll M.W., Liu C., Moss B., Rosenberg S.A., Restifo N.P. gp100/pmel 17 is a murine tumor rejection antigen: induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:1998;277-286.
21. + T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J. Immunol. 165:2000;6731-6737.
22. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., Donahoe S.M., Dunbar P.R., Cerundolo V., Nixon D.F., Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104:1999;173-180.
23. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1997;1183-1187.
24. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:1957;769-778.
25. Inaba K., Schuler G., Witmer M.D., Valinksy J., Atassi B., Steinman R.M. Immunologic properties of purified epidermal Langerhans cells. Distinct requirements for stimulation of unprimed and sensitized T lymphocytes. J. Exp. Med. 164:1986;605-613.
26. Labeur M.S., Roters B., Pers B., Mehling A., Luger T.A., Schwarz T., Grabbe S. Generation of tumor immunity by bone-marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:1999;168-175.
27. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., Nussenzweig M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:2001;769-779.
28. + T cells. The mice possess activated and cytolytic T cells but these T cells cannot proliferate in response to antigen.
29. + T cell tolerance. Immunity. 18:2003;713-720 This study developed a DC model capable of presenting an antigen either on a mature DC or on an immature DC. Depending on the maturational state of the DC, the same antigen resulted in tolerance or immunity.
30. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2:2001;947-950.
31. Trevejo J.M., Marino M.W., Philpott N., Josien R., Richards E.C., Elkon K.B., Falck-Pedersen E. TNF-α-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc. Natl. Acad. Sci. U S A. 98:2001;12162-12167.
32. Vance R.E. Cutting edge: cutting edge commentary: a Copernican revolution? Doubts about the danger theory. J. Immunol. 165:2000;1725-1728.
33. + T cells expanded in vitro with IL-15 and CD80 survived longer in vivo. IL-15 administration in vivo is also required to sustain anti-tumor activity in vivo.
34. Borrello I., Sotomayor E.M., Rattis F.M., Cooke S.K., Gu L., Levitsky H.I. Sustaining the graft-versus-tumor effect through post-transplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood. 95:2000;3011-3019.
35. ••].
36. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854 These studies demonstrate that in murine models and cancer patients lymphodepletion can enhance tumor immunity. This enhancement occurs during the induction phase, preferentially expanding reactive T cells and maintaining this T cell response during the effector phase.
37. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., Strome S.E., Pease L.R., Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109:2002;651-659 Using tumors that are refractory to 4-1BB tumor immunotherapy, this report demonstrates that these tumors are ignored by the immune system. Upon immunization, 4-1BB immunotherapy became effective against these tumors.
38. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P., Overwijk W.W., Restifo N.P., Melief C.J., Offringa R., et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:2001;481-489.
39. + T cells. Furthermore, CTLA-4 blockade induced tumor reactive T cells in murine models and in cancer patients.
40. ••].
41. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:2002;793-800 Both reports demonstrate that B7-H1 is not expressed by normal human tissues except for myleoid cells and that B7-H1 is upregulated on cancer cells. B7-H1 expression by cancer cells enables tumor escape and blockade of B7-H1 enhances tumor immunity.
42. ••]).
43. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., et al. Targeted disruption of the mouse transforming growth factor β1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
44. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., Rowley D.A. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. U S A. 87:1990;1486-1490.
45. Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor β signaling in T cells. Nat. Med. 7:2001;1118-1122.
46. Heckelsmiller K., Beck S., Rall K., Sipos B., Schlamp A., Tuma E., Rothenfusser S., Endres S., Hartmann G. Combined dendritic-cell- and CpG-oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32:2002;3235-3245 This report demonstrates that DC therapy in conjunction with CpG oligonucelotides rejects tumors that are resistant to 5-fluorouracil and leucovorin.
47. Fujii S., Shimizu K., Kronenberg M., Steinman R.M. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3:2002;867-874 This report shows that α-galactosylceramide bound to CD1 on DC can activate NKT cells. These NKT cells provide a more effective anti-tumor response through their own actions or by further maturing the DC to enhance other anti-tumor immune responses.
48. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., Dubensky T.W., Ying H., Restifo N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9:2003;33-39 This report demonstrates that alphavirus-based DNA vaccines induce the innate immune response through an RNaseI pathway. This pathway may enhance DC maturation, leading to more effective anti-tumor immunity.